The nonclinical safety evaluation of the anticancer drug ATRAGEN® (liposomal all-trans-retinoic acid)

International Journal of Toxicology

Volumn 19, Issue 1, 2000, Pages 33-42

  Wallace, Thomas L ^a,b   Larson, Jeffrey L ^a   Bazemore, Scott A ^a   Wilson, Chris W ^a   Cossum, Paul A ^a  

^a Antigenics Inc   (United States)

^b Aronex Pharmaceuticals   (United States)

Author keywords

All Trans Retinoic Acid; ATRAGEN; Liposomal Encapsulation; Nonclinical Toxicology; Pharmacokinetics; Tretinoin

Indexed keywords

ANTINEOPLASTIC AGENT; RETINOIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; ENCAPSULATION; FEMALE; MALE; NEPHROSIS; NONHUMAN; RAT; REPRODUCTIVE TOXICITY; RETINOL INTOXICATION; SPLEEN WEIGHT; TESTIS ATROPHY; TOXICITY TESTING;

ANIMALIA; CANIS FAMILIARIS;

EID: 0034067560     PISSN: 10915818     EISSN: None     Source Type: Journal    
DOI: 10.1080/109158100225024     Document Type: Article

References (14)

1. Armstrong, R. B., K. O. Ashenfelter, C. Eckhoff, A. A. Levin, and S. S. Shapiro. 1994. General and reproductive toxicology of retinoids. In The retinoids: Biology, chemistry, and medicine, 2nd ed., eds. M. B. Sporn, A. B. Roberts, and D. S. Goodman, 545-572. New York: Raven Press.
2. Aronex Study AR-92-41,075-001, Title: Phase I, open-label, dose escalating, multicenter, maximum tolerated dose study in patients with a broad variety of end-stage hematologic malignancies. Study date: November 5, 1998.
3. Chou, R. C., H. Burgin, G. Schmiit, and H. Egger. 1977. Absorption of tretinoin in rats and rabbits following oral and dermal application. Arzneim. Forsch. Drug Res. 47:401-405.
4. El Mansouri, S., M. Tod, M. Leclerq, O. Petitjean, G. Perret, and M. Porthault. 1995. Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). Drug Metab. Dispos. 23:227-231.
5. Fenaux, P., S. Castaigne, C. Chomienne, H. Dombret, and L. Degos. 1992. All trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia 6 (Suppl. 1):64-66.
6. Flynn, P., W. Miller, D. Weisdorf, D. Arthur, R. Brunning, and R. Branda. 1983. Retinoic acid treatment of acute promyelocytic leukemia: In vitro and in vivo observations. Blood 62:1211-1217.
7. Freireich, E. J., E. A. Gehan, D. P. Rail, L. H. Schmidt, and H. E. Skipper. 1966. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemolher. Rep. 50:219-244.
8. Kamm, J. J., K. O. Ashenfelter, and C. W. Ehmann. 1984. Preclinical and clinical toxicology of selected retinoids. In The retinoids, eds. M. B. Sporn, A. B. Roberts, and D. S. Goodman, 287-326. New York: Academic Press.
9. Kretzchmar, R., and F. Leuschner. 1975. Biosynthesis and metabolism of retinoic acid. Acta Dermatovener. Suppl. 74:25-28.
10. Kurtz, P. J., D. C. Emmerling, and D. J. Donofrio. 1984. Subchronic toxicity of all-trans-retinoic acid and retinylidene dimedone in Sprague-Dawley rats. Toxicology 30:115-124.
11. Shelley, R. S., H. W. Jun, J. C. Price, and D. E. Cadwallader. 1981. Blood level studies of all trans- and 13-cis-retinoic acids in rats using different formulations. J. Pharm. Sci. 71:904-907.
12. Teelman, K. 1983. Comparative toxicity of oral all-trans-retinoic acid and the aromatic retinoids Ro 10-9359 and Ro 12-7554 in rats: hematologic and biochemical studies. Drug Dev. Res. 3:49-57.
13. Warrell, R. P. Jr. 1996. Pathogenesis and management of acute promyelocytic leukemia. Ann. Rev. Med. 47:555-565.
14. Warrell, R. R. Jr., S. R. Frankel, W. H. Miller, Jr., D. A. Scheinberg, L. M. Itri, W. N. Hittelman, R. Vyas. M. Andreeff, A. Tafuri, A. Jakubowski, J. Gabrilove, M. S. Gordon, and E. Dmitrovsky. 1991. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N. Eng. J. Med. 324:1385-1393.